Registration Dossier

Diss Factsheets

Administrative data

Description of key information

A read-across of Corfree® M1 (consisting of46 wt% Dodecanedioic acid, 31 wt% Undecanedioic acid, 5 wt % Sebacic acid and 11 wt% other dibasic acids) with dodecanedioic acid indicates that it has been used experimentally in both parenteral and oral clinical alimentation studies. No adverse effects were reported at dose levels of up to 40g per person.
In an isolated case report occupational asthma was associated with exposure to soldering fumes from dodecanedioic acid containing flux.

Additional information

The major ingredient in Corfree® M1, Dodecanedioic acid, is rapidly and completely absorbed from the gastrointestinal tract. It is metabolised and incorporated in the fatty acid catabolism of the organism and has been proposed to be an intermediate in the beta-oxidation of long-chain fatty acids. Dodecanedioic acid is not or only to a small extent excreted renally. Dodecanedioic acid is devoid of any systemic adverse effects upon acute or repeated dosing. One single casuistic of occupational asthma was linked to exposure to decomposition fumes of dodecanedioic acid in soldering flux but the medical history of this isolated case is unclear.